
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc is demonstrating a positive outlook as it advances its clinical-stage pipeline, particularly with RLY-2608, which shows a notable overall response rate (ORR) of 38.7% and improved median progression-free survival (mPFS) of 9.2 months, extending to 11.4 months among patients with kinase mutations. The recent data suggests that RLY-2608 offers better tolerability and dose intensity, resulting in longer durability for breast cancer patients, thereby enhancing its therapeutic potential. Additionally, the FDA approval of Truqap (capivasertib) + Faslodex reinforces the validity of targeting the PI3K/AKT pathway in treating advanced breast cancer, showcasing the significant advancements in Relay Therapeutics' precision medicine approach.
Bears say
Relay Therapeutics Inc. is projected to experience a widening net loss, anticipated at $2.15 per share for the full year 2025, indicating ongoing financial challenges for the company. There are numerous significant risks affecting the company's outlook, including the potential for negative clinical data, slower-than-expected development timelines, and setbacks in both earlier and later-stage trials, which could hinder approval and commercialization of its drug candidates. This backdrop of increasing losses combined with competitive landscape risks and potential dilution adds to the negative outlook on the company's financial health and future viability in the market.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares